Scinai Immunotherapeutics Ltd. (SCNI) Form 6-K — Oct 13, 2026
Scinai Immunotherapeutics (Nasdaq: SCNI) announced a definitive $5.1 million development and clinical manufacturing agreement signed by its subsidiary Scinai Biopharma Services with a U.S.-based, Nasdaq-listed biopharmaceutical company. The engagement covers CMC development, IND-enabling activities, and clinical manufacturing for an investigational oncology product, with revenue contributions expected in 2026 and 2027.
Key figures
- Committed customer orders usd
- 7600000
- Committed base service fees usd
- 5100000
- Potential uncommitted service fees usd
- 5850000
- Committed customer orders aug 16 2026 usd
- 3100000
- Committed customer orders year end 2025 usd
- 1900000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.